Objectives: To identify determinants of clinical outcomes following primary percutaneous
coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) …

Acute coronary syndrome (ACS) continues to contribute to the significant morbidity and
mortality related to cardiac disease, which remains the leading cause of death in the United …

Abstract Purpose of Review Antiplatelet therapy for patients undergoing percutaneous
coronary intervention has rapidly evolved over the last 10 years, often outpacing clinical …

The wide availability of effective drugs in reducing cardiovascular events together with the
use of myocardial revascularization has greatly improved the prognosis of patients with …

Objectives: Prevention of adverse ischemic events during and after primary percutaneous
coronary intervention (PCI) in patients with acute myocardial infarction (AMI) is the essential …

Potent adjunctive parenteral anticoagulants in addition to dual antiplatelet therapy are
recommended for the treatment of ST-elevation myocardial infarction (STEMI) with primary …

Patients with acute coronary syndrome and who undergo percutaneous coronary
intervention are at a high risk for recurrent adverse cardiovascular events. There is a …

Antiplatelet therapy is a cornerstone in the prevention and management of acute and
chronic ischaemic cardiovascular disease. 1–3 Implicit in the decisions regarding initiation …

Background: Recent data suggest that Bivalirudin provides ischemic protection superior to
Heparin, and comparable to Heparin plus glycoprotein IIb/IIIa inhibitors, with significantly …

Percutaneous coronary intervention (PCI) was made possible by the pioneering work of
Andreas Gruentzig, who in 1977 performed the first angioplasty procedure. Ongoing …